Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Net Margin (2016 - 2025)

Vanda Pharmaceuticals' Net Margin history spans 16 years, with the latest figure at 246.83% for Q4 2025.

  • On a quarterly basis, Net Margin fell 23767.0% to 246.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 102.03%, a 9253.0% decrease, with the full-year FY2025 number at 102.02%, down 9251.0% from a year prior.
  • Net Margin hit 246.83% in Q4 2025 for Vanda Pharmaceuticals, down from 40.15% in the prior quarter.
  • Over the last five years, Net Margin for VNDA hit a ceiling of 14.14% in Q2 2021 and a floor of 246.83% in Q4 2025.
  • Historically, Net Margin has averaged 18.69% across 5 years, with a median of 2.47% in 2023.
  • Biggest five-year swings in Net Margin: surged 1594bps in 2023 and later crashed -23767bps in 2025.
  • Tracing VNDA's Net Margin over 5 years: stood at 10.44% in 2021, then increased by 2bps to 10.64% in 2022, then crashed by -150bps to 5.3% in 2023, then crashed by -73bps to 9.17% in 2024, then plummeted by -2592bps to 246.83% in 2025.
  • Business Quant data shows Net Margin for VNDA at 246.83% in Q4 2025, 40.15% in Q3 2025, and 51.73% in Q2 2025.